On March 2, Shenzhen Yishi Kangning Biological Technology Co., Ltd. held the fifth anniversary celebration party in Nankunshan Grand View Garden. Five years ago, Professor Liu Yong, the inventor of ACTL's targeted anti-tumor immune technology, and his team established ISKCO...

Recently, we reviewed the investigational treatment of a group of patients. All 19 patients started ACTL treatment after the previous treatment failed. These include common solid tumors such as lung cancer and colorectal cancer, as well as rare cancers such as thymoma. These patients are all...

On the occasion of the 2017 New Year's Day holiday, Shenzhen Yishi Kangning Biotechnology Co., Ltd. would like to extend sincere greetings to all patients and friends! To the experts, scholars and technicians who have made contributions to the development of anti-tumor therapy for a long ...

On the morning of November 18, the ACTL Technology (Hainan) Center officially started construction in Boao, Hainan. Chai Xiaorong, chairman of Shenzhen Yishi Kangning Biotechnology Co., Ltd., and Professor Liu Yong, chief scientist and ACTL technology inventor, attended the...

At 9 am on September 1, the Shenzhen Science and Technology Innovation Conference and the Sixth Representative Conference of the Shenzhen Association for Science and Technology were held in Wuzhou Hotel. The Shenzhen Science and Technology Award was awarded at the conference and...